Swedish “digital contraception” app Natural Cycles raises $30M Series B led by EQT Ventures
Context & Ripple Effects
Natural Cycles' $30M Series B lands mid-way through a Swedish digital-health funding run: period-tracking rival Clue had already pulled in $7M to build a female-health platform two years earlier, and video-consultation startup KRY closed a €20M Series A led by Accel just months before this round.
The raise matters because it moves contraception software from tracker territory toward regulated medicine — a bet vindicated years later when the company returned with an FDA-cleared app, ~3M users, and a $55M Series C that pushed total funding past $95M.
First-order effects
- EQT Ventures' capital gives Natural Cycles the runway to scale its app-based contraception beyond its Swedish base, making it the best-funded player in the Nordic femtech cluster alongside Clue and KRY.
Second-order effects
- US direct-to-consumer birth control entrants take note of the category's fundraising velocity — Nurx went on to raise a $32M Series C plus $20M in debt at a reported ~$300M valuation, confirming investor appetite for app-delivered contraception.
Third-order effects
- The pattern points toward consumer health apps pursuing formal regulatory clearance rather than staying wellness products — Natural Cycles' eventual FDA-cleared status became the template its successors fundraise against.
The trend: Consumer health apps are graduating from unregulated trackers to clinically cleared medical devices, with successive venture rounds tracking each step up the regulatory ladder.